ClinicalTrials.gg
CompletedNCT06037148Updated Mar 25, 2024

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

A Phase 1 interventional study of DM-101PX and Placebo to Match DM-101PX in Birch Pollen Allergy, sponsored by Desentum Oy. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by Desentum Oy · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada — 2 open to participants now, 3 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · Canada.

Enrollment
30th of 32
30 · median 104
Started
2023
with 3 others
Phase 1
4 of 33
none open now
Registered
28th of 33
by date
Lead sponsor
2 of 33
Desentum Oy

Among the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, this one is the 30th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2023, is one of 4 in phase 1, and was the 28th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

2 of the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, or all of them as a file.
02

Study summary

Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of three ascending dosing schemes of DM-101-PX in birch pollen allergic adults. As an explorative objective, the trial will also investigate the effect of DM-101PX on the allergic symptoms following birch pollen allergen exposure in a chamber. Expanded access to the study treatment is not available.

Read the detailed description

The study will be carried out in a single study site located in Canada

03

Conditions studied

  • Birch Pollen Allergy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Either sex or any race, aged 18 to 65 years
  • Good general health
  • A documented clinical history of moderate to severe birch pollen induced allergic rhinitis or rhinoconjunctivitis with symptoms that interfere with daily activities or sleep and remain bothersome despite the use of relevant symptomatic medication, and have been present over at least 2 previous birch pollen seasons
  • Birch pollen specific IgE ≥ 0.7 kU/L
  • Positive SPT to birch pollen allergen, with wheal diameter ≥ 3 mm
  • Body weight ≥ 50 kg and within the range of 18-35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History or findings on physical examination of any significant disease or disorder which, in the opinion of the Investigator, could put the subject at risk because of participation in the trial, influence the results of the trial or subject's ability to participate in the trial
  • Current diagnosis of persistent asthma, or moderate to severe asthma requiring GINA Step 2 or higher treatment, or asthma partially controlled or uncontrolled according to GINA classification in the 6 months before screening
  • Significant rhinitis, sinusitis, significant and/or severe allergies not associated with the birch pollen season
  • History of asthma deterioration that resulted in emergency treatment or hospitalization in the past 12 months before screening, or a life-threatening asthma attack at any time in the past
  • A (FEV1) ≤ 75% of predicted value
  • History of severe drug allergy, severe angioedema, or systemic allergic reaction of Grade 3 or grater, according to World Allergy Organization (WAO) scale, due to any cause
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    DM-101PX low dose

    10 subcutaneous doses starting from 0.05 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.

    Biological: DM-101PX

  • Placebo comparator
    Placebo

    10 subcutaneous doses.First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.

    Biological: Placebo to Match DM-101PX

  • Experimental
    DM-101PX middle dose

    10 subcutaneous doses starting from 0.1 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.

    Biological: DM-101PX

  • Experimental
    DM-101PX high dose

    10 subcutaneous doses starting from 0.2 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.

    Biological: DM-101PX

Interventions

  • BiologicalDM-101PX

    subcutaneous injection of DM-101PX

  • BiologicalPlacebo to Match DM-101PX

    Placebo to match DM-101PX administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events

    Occurrence of treatment emergent adverse events

    Time frame: From the first dose to until 14-28 days from the last dose

  2. Adverse Events of Special Interest

    Occurrence of local injection site reactions and systemic allergic reactions

    Time frame: From the first dose to until 14-28 days from the last dose

Secondary outcomes

  1. Subjects Reaching the Maximum Intended Dose

    Number of subjects in each cohort who reach the maximum intended dose

    Time frame: Through the treatment period, an average of 10 weeks

07

Study locations

1 site
  • Cliantha Research
    Mississauga, Ontario ON L4W 1A4, Canada
08

References and documents

Individual participant data

Plan to share: Yes — All individual participant data that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to patient level data and related study documents: patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants after Desentum has received marketing authorization from major health authorities (e.g. FDA, EMA), has the legal authority to share the data, and has made the study results publicly available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Mar 2024, 5 months.

Of 16 phase 1 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 9. This study's 5 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 14, 2023
StartActual
Sep 7, 2023
Primary completionActual
Mar 6, 2024
CompletionActual
Mar 6, 2024
Last update
Mar 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06037148
Lead sponsor
Desentum Oy
Responsible party
Sponsor
First posted
Sep 14, 2023
Start date
Sep 7, 2023
Primary completion
Mar 6, 2024
Completion
Mar 6, 2024
Last update
Mar 25, 2024

Study contacts

Anna Nilson
study director · Desentum Oy
Patricia Couroux
principal investigator · Cliantha Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DM-101PX

Start the discussion